Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Petusky from Barrington maintained a Buy rating on the stock and has a $90.00 price target.
Michael Petusky has given his Buy rating due to a combination of factors including Henry Schein’s future growth prospects and financial guidance. Despite a slight miss in revenue and earnings expectations for the recent quarter, the company maintains a positive outlook for 2025, with anticipated earnings per share growth and revenue increases.
The company’s strategic changes in segment reporting and consistent cash flow generation also contribute to the positive assessment. Furthermore, Petusky’s price target of $90 reflects confidence in the company’s ability to achieve mid-single-digit adjusted EBITDA growth, supported by a manageable level of net debt. These elements collectively underpin the Outperform rating for HSIC shares.
According to TipRanks, Petusky is a 4-star analyst with an average return of 4.1% and a 49.38% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Haemonetics, Merit Medical Systems, and Henry Schein.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $90.00 price target.